Kim Sukyung, Rahim Md Abdur, Tajdozian Hanieh, Barman Indrajeet, Park Hyun-A, Yoon Youjin, Jo Sujin, Lee Soyeon, Shuvo Md Sarower Hossen, Bae Sung Hae, Lee Hyunji, Ju Sehee, Park Chae-Eun, Kim Ho-Kyoung, Han Jeung Hi, Kim Ji-Woong, Yoon Sung Geon, Kim Jae Hong, Choi Yang Gyu, Lee Saebim, Seo Hoonhee, Song Ho-Yeon
Human Microbiome Medical Center (HM·MRC), Soonchunhyang University, 22, Soonchunhyang-ro, Sinchang-myeon, Asan-si 31538, Chungnam, Republic of Korea.
Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, 31, Suncheonhyang 6-gil, Dongnam-gu, Cheonan-si 31151, Chungnam, Republic of Korea.
Cells. 2024 Dec 9;13(23):2029. doi: 10.3390/cells13232029.
Xerosis, characterized by dry, rough skin, causes discomfort and aesthetic concerns, necessitating effective treatment. Traditional treatments often show limited efficacy, prompting the need for innovative therapies. This study highlights the efficacy of microbiome therapeutic LP51, derived from a healthy vaginal microbiome, in improving xerosis. A double-blind clinical trial involving 43 subjects with dry inner arm skin compared the effects of a 2.9% LP51 extract formulation to a placebo over 4 weeks. The LP51 group exhibited a significant increase in stratum corneum hydration (10.0 A.U.) compared to the placebo group (4.8 A.U.) and a 21.4% decrease in transepidermal water loss (TEWL), whereas the placebo group showed no significant change. LP51 also demonstrated benefits in enhancing skin hydration, improving the skin barrier, and exhibited anti-atopic, anti-inflammatory, and antioxidant properties. Safety was confirmed through in vitro cytotoxicity tests. These effects are attributed to the microbiome-safe component in LP51 and its role in improving xerosis, reflected by an increase in the xerosis-microbiome index, defined by the Firmicutes/Actinobacteria ratio. These findings position microbiome therapeutic LP51 as a promising novel treatment for xerosis.
皮肤干燥症以皮肤干燥、粗糙为特征，会引起不适并影响美观，因此需要有效的治疗方法。传统治疗方法往往疗效有限，这促使人们寻求创新疗法。本研究强调了源自健康阴道微生物群的微生物治疗剂LP51在改善皮肤干燥症方面的疗效。一项针对43名上臂内侧皮肤干燥受试者的双盲临床试验，比较了2.9%LP51提取物制剂与安慰剂在4周内的效果。与安慰剂组（4.8任意单位）相比，LP51组的角质层水合作用显著增加（10.0任意单位），经表皮水分流失（TEWL）减少了21.4%，而安慰剂组没有显著变化。LP51在增强皮肤水合作用、改善皮肤屏障方面也显示出益处，并具有抗特应性、抗炎和抗氧化特性。通过体外细胞毒性试验证实了其安全性。这些作用归因于LP51中的微生物安全成分及其在改善皮肤干燥症中的作用，这一点通过以厚壁菌门/放线菌门比率定义的皮肤干燥症-微生物群指数的增加得到体现。这些发现表明微生物治疗剂LP51是一种有前景的治疗皮肤干燥症的新型疗法。
